Pirfenidone and immunotherapy with optional radiation for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of three treatments—pirfenidone (an anti-scarring drug), a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), and sometimes radiation—for colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can slow or shrink your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed colorectal cancer that is advanced or has spread, with a specific genetic marker (MSS or pMMR status)
- Cancer has progressed despite standard treatment, or you are unable to tolerate or access standard options
- Age between 18 and 75 years old
- Blood work, liver function, kidney function, and clotting tests must be within safe ranges (tests done within 7 days before starting)
- Good overall health and ability to perform daily activities (ECOG score 0 or 1)
- No active brain tumors, seizures, spinal cord compression, or serious heart/lung disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a very low dose of radiation to a combination of immunotherapy (pucotenlimab) and chemotherapy (CAPEOX) can help shrink rectal cancer tumors that have not spread. It is for people with locally advanced rectal cancer that is pMMR (meaning the cancer cells have normal DNA repair).
This trial tests a new combination of three drugs—fruquintinib (a targeted therapy), pirfenidone (an anti-fibrotic drug), and an immunotherapy (anti-PD-1)—for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this triple therapy can shrink tumors more effectively than current options.
This trial studies whether giving focused radiation (SBRT) together with fruquintinib and immune drugs (PD-1/CTLA-4) can control advanced, hard-to-remove colorectal cancer. It is for people whose cancer has grown despite standard first- and second-line chemotherapy.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
This trial tests a new combination—an immunotherapy drug (cadonilimab) plus a targeted anti-angiogenesis pill (fruquintinib) and focused radiation (SBRT)—for people with MSS colorectal cancer that has progressed after at least two prior treatments. The goal is to see if this triple approach can help shrink or control the cancer better than standard options.
This trial tests a new combination of two drugs, pirfenidone and sintilimab, added to standard chemotherapy before surgery for colorectal cancer that has spread to the lining of the abdomen (peritoneal metastasis). The goal is to see if this combination helps shrink the cancer more effectively.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.